The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Size Of The Tremfya Market Progress Through 2030?
The historic period’s growth stemmed from a rising incidence of psoriasis and psoriatic arthritis, the effective clinical performance of biologic treatments, an expansion in specialized dermatology services, enhanced patient commitment to biologic medications, and broader reimbursement availability for biologic pharmaceuticals.
Anticipated market expansion is primarily driven by a heightened need for sustained inflammatory condition management, the broader application of biologics in gastroenterological disorders, an increasing inclination towards less frequent drug administration, greater investment in monoclonal antibody therapies, and an escalating emphasis on personalized immunology treatments.
Prominent patterns anticipated during the forecast period encompass a wider adoption of IL-23 inhibitor therapies, an escalating need for biologic treatments administered at longer intervals, the broadening spectrum of autoimmune disease applications, a surge in the use of subcutaneous biologic injections, and a stronger concentration on targeted immunomodulation.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp
What Core Drivers Are Transforming The Tremfya Market?
The **tremfya market** is anticipated to expand due to the growing occurrence of autoimmune diseases. These are conditions where the immune system incorrectly targets the body’s own cells, tissues, or organs, treating them as external threats. This increase in prevalence can be attributed to factors such as genetic susceptibility, environmental catalysts, shifts in lifestyle, greater public awareness, and advancements in diagnostic methods. As a monoclonal antibody, **Tremfya** targets interleukin-23 (IL-23) to address autoimmune disorders by adjusting the immune system’s excessive reaction, decreasing inflammation, and easing symptoms in conditions like psoriasis and psoriatic arthritis. For example, data from Arthritis Australia in February 2024 indicates that by 2025, approximately **212,136 males** and **362,137 females** are forecast to have **rheumatoid arthritis (RA)**. This figure is projected to climb by 2040, reaching around **280,040 males** and **479,828 females**. Consequently, the rising incidence of autoimmune diseases is fueling the expansion of the **tremfya market**.
How Is The Tremfya Market Examined Through Segment Analysis?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By End User: Adult Patients, Geriatric Patients
Which Trends Are Influencing The Direction Of The Tremfya Market?
Major entities operating in the tremfya market are securing regulatory clearances to broaden its treatment applications, such as for moderate-to-severe Crohn’s disease, thereby expanding its patient population and market opportunities. Regulatory approvals denote the formal authorization granted by bodies like the Food and Drug Administration (FDA) or European Medicines Agency (EMA), enabling a medication to be marketed for specific uses after its safety, effectiveness, and quality have been established. For instance, in September 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained FDA approval for TREMFYA (guselkumab) for treating adults with moderately to severely active ulcerative colitis, making it the first dual-acting interleukin-23 inhibitor authorized for this condition. This decision is underpinned by positive findings from the Phase 2b/3 QUASAR study, which indicated that approximately 50% of patients achieved clinical remission after 44 weeks of treatment. TREMFYA targets interleukin-23, assisting in the normalization of the inflammatory response in the colon.
Which Organizations Are Operating Within The Tremfya Market?
Major companies operating in the tremfya market are Johnson & Johnson
Access The Complete Tremfya Market Report:
https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report
What Is The Largest Regional Market In The Tremfya Market?
North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model